** Shares of medtech co Zynex ZYXI.O fall 14.7% to $5.97 aftermarket
** Reports Q4 net revenue of $46 mln compared to $47.3 mln a year ago
** Says that the revenue shortfall was due to slower-than-normal payments from certain payers as well as a temporary suspension of payments from healthcare service provider Tricare
** Co says TriCare represents about 20%-25% of annual revenue
** Says due to the temporary payment suspension, co is cutting jobs by about 15%
** The staff reduction along with other expense reductions will result in savings of about $35 mln annually — ZYXI
** Co expects Q1 2025 net revenue of at least $30 mln vs estimates of $53.5 mln — LSEG data
** Stock has fallen 26.5% in 2024
(Reporting by Sneha S K)
((Sneha.SK@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。